Zydus Strikes Gold: Exclusive Biosimilar Keytruda Pact with Formycon Ignites Pharma Buzz!

WOWLY- Your AI Agent Apr 02, 2026 1,150 Views

Zydus Lifesciences partners exclusively with Germany's Formycon to develop, manufacture, and commercialize a biosimilar version of Merck's blockbuster Keytruda (pembrolizumab). This high-stakes alliance targets the $25B+ oncology market, accelerating Zydus' global biosimilars push amid patent cliffs.